These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 12270162)

  • 1. Combinatorial library of indinavir analogues: replacement for the aminoindanol at P2'.
    Raghavan S; Yang Z; Mosley RT; Schleif WA; Gabryelski L; Olsen DB; Stahlhut M; Kuo LC; Emini EA; Chapman KT; Tata JR
    Bioorg Med Chem Lett; 2002 Oct; 12(20):2855-8. PubMed ID: 12270162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combinatorial diversification of indinavir: in vivo mixture dosing of an HIV protease inhibitor library.
    Rano TA; Cheng Y; Huening TT; Zhang F; Schleif WA; Gabryelski L; Olsen DB; Kuo LC; Lin JH; Xu X; Olah TV; McLoughlin DA; King R; Chapman KT; Tata JR
    Bioorg Med Chem Lett; 2000 Jul; 10(14):1527-30. PubMed ID: 10915042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A combinatorial library of indinavir analogues and its in vitro and in vivo studies.
    Cheng Y; Rano TA; Huening TT; Zhang F; Lu Z; Schleif WA; Gabryelski L; Olsen DB; Stahlhut M; Kuo LC; Lin JH; Xu X; Jin L; Olah TV; McLoughlin DA; King RC; Chapman KT; Tata JR
    Bioorg Med Chem Lett; 2002 Feb; 12(4):529-32. PubMed ID: 11844665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solid phase synthesis of indinavir and its analogues.
    Cheng Y; Lu Z; Chapman KT; Tata JR
    J Comb Chem; 2000; 2(5):445-6. PubMed ID: 11029167
    [No Abstract]   [Full Text] [Related]  

  • 5. Synthesis and activity of novel HIV protease inhibitors with improved potency against multiple PI-resistant viral strains.
    Duffy JL; Kevin NJ; Kirk BA; Chapman KT; Schleif WA; Olsen DB; Stahlhut M; Rutkowski CA; Kuo LC; Jin L; Lin JH; Emini EA; Tata JR
    Bioorg Med Chem Lett; 2002 Sep; 12(17):2423-6. PubMed ID: 12161148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indinavir analogues with blocked metabolism sites as HIV protease inhibitors with improved pharmacological profiles and high potency against PI-resistant viral strains.
    Cheng Y; Zhang F; Rano TA; Lu Z; Schleif WA; Gabryelski L; Olsen DB; Stahlhut M; Rutkowski CA; Lin JH; Jin L; Emini EA; Chapman KT; Tata JR
    Bioorg Med Chem Lett; 2002 Sep; 12(17):2419-22. PubMed ID: 12161147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of HIV-1 protease inhibitors. Novel tetrahydrofuran P2/P2'-groups interacting with Asp29/30 of the HIV-1 protease. Determination of binding from X-ray crystal structure of inhibitor protease complex.
    Oscarsson K; Lahmann M; Lindberg J; Kangasmetsä J; Unge T; Oscarson S; Hallberg A; Samuelsson B
    Bioorg Med Chem; 2003 Mar; 11(6):1107-15. PubMed ID: 12614898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent cyclic urea HIV protease inhibitors with 3-aminoindazole P2/P2' groups.
    Rodgers JD; Johnson BL; Wang H; Erickson-Viitanen S; Klabe RM; Bacheler L; Cordova BC; Chang CH
    Bioorg Med Chem Lett; 1998 Apr; 8(7):715-20. PubMed ID: 9871528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of novel HIV protease inhibitors (PI) with activity against PI-resistant virus.
    Raghavan S; Lu Z; Beeson T; Chapman KT; Schleif WA; Olsen DB; Stahlhut M; Rutkowski CA; Gabryelski L; Emini E; Tata JR
    Bioorg Med Chem Lett; 2007 Oct; 17(19):5432-6. PubMed ID: 17692518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of sulfoximine based inhibitors for HIV-1 protease.
    Raza A; Sham YY; Vince R
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5406-10. PubMed ID: 18829317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus.
    Lu Z; Bohn J; Rano T; Rutkowski CA; Simcoe AL; Olsen DB; Schleif WA; Carella A; Gabryelski L; Jin L; Lin JH; Emini E; Chapman K; Tata JR
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5311-4. PubMed ID: 16203148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.
    Smith AB; Charnley AK; Harada H; Beiger JJ; Cantin LD; Kenesky CS; Hirschmann R; Munshi S; Olsen DB; Stahlhut MW; Schleif WA; Kuo LC
    Bioorg Med Chem Lett; 2006 Feb; 16(4):859-63. PubMed ID: 16298527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir.
    Kevin NJ; Duffy JL; Kirk BA; Chapman KT; Schleif WA; Olsen DB; Stahlhut M; Rutkowski CA; Kuo LC; Jin L; Lin JH; Emini EA; Tata JR
    Bioorg Med Chem Lett; 2003 Nov; 13(22):4027-30. PubMed ID: 14592500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease.
    King NM; Melnick L; Prabu-Jeyabalan M; Nalivaika EA; Yang SS; Gao Y; Nie X; Zepp C; Heefner DL; Schiffer CA
    Protein Sci; 2002 Feb; 11(2):418-29. PubMed ID: 11790852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta-lactam compounds as apparently uncompetitive inhibitors of HIV-1 protease.
    Sperka T; Pitlik J; Bagossi P; Tözsér J
    Bioorg Med Chem Lett; 2005 Jun; 15(12):3086-90. PubMed ID: 15893929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of low molecular weight HIV-1 protease dimerization inhibitors.
    Hwang YS; Chmielewski J
    J Med Chem; 2005 Mar; 48(6):2239-42. PubMed ID: 15771466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P2' benzene carboxylic acid moiety is associated with decrease in cellular uptake: evaluation of novel nonpeptidic HIV-1 protease inhibitors containing P2 bis-tetrahydrofuran moiety.
    Yedidi RS; Maeda K; Fyvie WS; Steffey M; Davis DA; Palmer I; Aoki M; Kaufman JD; Stahl SJ; Garimella H; Das D; Wingfield PT; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2013 Oct; 57(10):4920-7. PubMed ID: 23877703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P1' oxadiazole protease inhibitors with excellent activity against native and protease inhibitor-resistant HIV-1.
    Kim RM; Rouse EA; Chapman KT; Schleif WA; Olsen DB; Stahlhut M; Rutkowski CA; Emini EA; Tata JR
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4651-4. PubMed ID: 15324882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rational design, synthesis, and crystallographic analysis of a hydroxyethylene-based HIV-1 protease inhibitor containing a heterocyclic P1'--P2' amide bond isostere.
    Thompson SK; Murthy KH; Zhao B; Winborne E; Green DW; Fisher SM; DesJarlais RL; Tomaszek TA; Meek TD; Gleason JG
    J Med Chem; 1994 Sep; 37(19):3100-7. PubMed ID: 7932533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid discovery and structure-activity profiling of novel inhibitors of human immunodeficiency virus type 1 protease enabled by the copper(I)-catalyzed synthesis of 1,2,3-triazoles and their further functionalization.
    Whiting M; Tripp JC; Lin YC; Lindstrom W; Olson AJ; Elder JH; Sharpless KB; Fokin VV
    J Med Chem; 2006 Dec; 49(26):7697-710. PubMed ID: 17181152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.